JP2020519614A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020519614A5 JP2020519614A5 JP2019561944A JP2019561944A JP2020519614A5 JP 2020519614 A5 JP2020519614 A5 JP 2020519614A5 JP 2019561944 A JP2019561944 A JP 2019561944A JP 2019561944 A JP2019561944 A JP 2019561944A JP 2020519614 A5 JP2020519614 A5 JP 2020519614A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer
- tgf beta
- agent
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762503405P | 2017-05-09 | 2017-05-09 | |
| US62/503,405 | 2017-05-09 | ||
| PCT/US2018/031501 WO2018208720A1 (en) | 2017-05-09 | 2018-05-08 | Combination pdl1 and tgf-beta blockade in patients with hpv+ malignancies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020519614A JP2020519614A (ja) | 2020-07-02 |
| JP2020519614A5 true JP2020519614A5 (enExample) | 2021-06-10 |
| JP7340458B2 JP7340458B2 (ja) | 2023-09-07 |
Family
ID=62530530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019561944A Active JP7340458B2 (ja) | 2017-05-09 | 2018-05-08 | Ｈｐｖ＋悪性腫瘍を有する患者におけるｐｄｌ１とｔｇｆベータの遮断の組み合わせ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11440963B2 (enExample) |
| EP (1) | EP3624895B1 (enExample) |
| JP (1) | JP7340458B2 (enExample) |
| AU (1) | AU2018266103B2 (enExample) |
| WO (1) | WO2018208720A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11583593B2 (en) | 2016-01-14 | 2023-02-21 | Synthis Therapeutics, Inc. | Antibody-ALK5 inhibitor conjugates and their uses |
| AU2018431586B2 (en) * | 2018-07-09 | 2025-03-20 | Synthis Therapeutics, Inc | Antibody-ALK5 inhibitor conjugates and their uses |
| CN112672753B (zh) * | 2018-07-09 | 2025-07-08 | 普瑞赛格恩公司 | 融合构建体及其使用方法 |
| SG11202105975SA (en) * | 2018-12-06 | 2021-07-29 | Guangdong Tcrcure Biopharma Technology Co Ltd | Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints |
| WO2021061437A1 (en) * | 2019-09-12 | 2021-04-01 | Sirnaomics, Inc. | CO-DELIVERY OF TGF-β SIRNA AND PDL1 SIRNA TO TREAT CANCER |
| US20230044248A1 (en) | 2019-11-01 | 2023-02-09 | Ares Trading S.A. | COMBINED INHIBITION OF PD-1, TGFBeta AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER |
| US20230340122A1 (en) | 2019-11-05 | 2023-10-26 | Glaxosmithkline Intellectual Property (No. 4) Ltd. | Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer |
| TW202128763A (zh) * | 2019-11-12 | 2021-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 含有ＴＧＦ－β受體的融合蛋白及其醫藥用途 |
| WO2021123432A1 (en) | 2019-12-20 | 2021-06-24 | Ares Trading S.A. | Igg:tgfbetarii fusion protein composition |
| EP3838260A1 (en) | 2019-12-20 | 2021-06-23 | Ares Trading S.A. | Igg:tgf rii fusion protein composition |
| WO2021209458A1 (en) | 2020-04-14 | 2021-10-21 | Ares Trading S.A. | Combination treatment of cancer |
| AU2021256925A1 (en) * | 2020-04-14 | 2022-11-03 | Ares Trading S.A. | Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein |
| US12194094B2 (en) | 2020-07-10 | 2025-01-14 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| US20230372319A1 (en) | 2020-11-02 | 2023-11-23 | Ares Trading S.A. | Combination Treatment of Cancer |
| WO2022090527A1 (en) | 2020-11-02 | 2022-05-05 | Ares Trading S.A. | Combination treatment of cancer |
| JP2023550419A (ja) * | 2020-11-18 | 2023-12-01 | スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド | 二機能性分子 |
| US20250281633A1 (en) | 2021-05-03 | 2025-09-11 | Merck Patent Gmbh | Her2 targeting fc antigen binding fragment-drug conjugates |
| US20240226319A1 (en) | 2021-05-25 | 2024-07-11 | Merck Patent Gmbh | Egfr targeting fc antigen binding fragment-drug conjugates |
| EP4351640A1 (en) | 2021-06-07 | 2024-04-17 | Ares Trading S.A. | Combination treatment of cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| CA2678404C (en) | 2007-02-28 | 2019-03-19 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Brachyury polypeptides and methods for use |
| WO2014043535A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
| WO2014043518A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
| HRP20210977T1 (hr) * | 2014-02-10 | 2021-09-17 | Merck Patent Gmbh | Ciljano inhibiranje tgf beta |
| CN107428825A (zh) | 2014-10-10 | 2017-12-01 | 创祐生技股份有限公司 | 治疗及/或预防肿瘤生长、侵袭及/或转移的方法 |
-
2018
- 2018-05-08 AU AU2018266103A patent/AU2018266103B2/en active Active
- 2018-05-08 US US16/612,495 patent/US11440963B2/en active Active
- 2018-05-08 JP JP2019561944A patent/JP7340458B2/ja active Active
- 2018-05-08 EP EP18729515.9A patent/EP3624895B1/en active Active
- 2018-05-08 WO PCT/US2018/031501 patent/WO2018208720A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Khairkhah et al. | Current and future direction in treatment of HPV-related cervical disease | |
| Nunes et al. | Innate immunity and HPV: friends or foes | |
| Van Der Burg et al. | Therapeutic vaccination against human papilloma virus induced malignancies | |
| Frazer | Prevention of cervical cancer through papillomavirus vaccination | |
| Brentjens et al. | Human papillomavirus: a review | |
| Guo et al. | Cervical cancer: emerging immune landscape and treatment | |
| Trimble et al. | Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial | |
| Doorbar | Papillomavirus life cycle organization and biomarker selection | |
| Torres-Poveda et al. | Role of IL-10 and TGF-β1 in local immunosuppression in HPV-associated cervical neoplasia | |
| Furumoto et al. | Human papilloma virus (HPV) and cervical cancer | |
| Syrjänen | The role of human papillomavirus infection in head and neck cancers | |
| Vu et al. | HPV-induced oropharyngeal cancer, immune response and response to therapy | |
| Kimberlin | Current status of antiviral therapy for juvenile-onset recurrent respiratory papillomatosis | |
| Gondivkar et al. | Involvement of viral factors with head and neck cancers | |
| Galliverti et al. | Nanoparticle conjugation of human papillomavirus 16 E7-long peptides enhances therapeutic vaccine efficacy against solid tumors in mice | |
| Wang et al. | Immunoprevention of human papillomavirus–associated malignancies | |
| Galloway | Is vaccination against human papillomavirus a possibility? | |
| Brinkman et al. | Therapeutic vaccination for HPV induced cervical cancers | |
| Hughes et al. | Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus | |
| Bava et al. | Cervical cancer: A comprehensive approach towards extermination | |
| Liao et al. | Single-dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein | |
| Hoffmann et al. | Combining T-cell vaccination and application of agonistic anti-GITR mAb (DTA-1) induces complete eradication of HPV oncogene expressing tumors in mice | |
| Ji et al. | Viral vector-based therapeutic HPV vaccines | |
| Shih et al. | Anti-viral treatment and cancer control | |
| Koonsaeng et al. | Successful treatment of recurrent vulvar intraepithelial neoplasia resistant to interferon and isotretinoin with cidofovir |